TEXAS MEDICAID
Clinical Edit Prior Authorization
sarilumab (KEVZARA)

STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING	
Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:

STEP 2: MEDICATION INFORMATION	
Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:

Patient's Primary Diagnosis: _____ ICD 10 Code: _____

Please indicate ONE (1) of the following:

☐ STAR / STAR KIDS client **(Go to Step 3 - PDL PA Criteria Applies)**

OR ☐ CHIP / PERINATE client **(Go to Step 4)**

STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT

1. Has the client failed a 30-day treatment trial with at least one (1) preferred agent in the last 180 days?

   ☐ Yes (Go to Step 4 Question 1) ☐ No (Go to #2)

2. Is there a documented allergy or contraindication to preferred agents in this class?

   ☐ Yes (Go to Step 4 Question 1) ☐ No (Go to #3)

3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?

   ☐ Yes (Go to Step 4 Question 1) ☐ No (Deny)

STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA

1. Is the client greater than or equal to (≥) 18 years of age?

   ☐ Yes (Go to #2) ☐ No (Deny)

2. Does the client have a diagnosis of Rheumatoid Arthritis (RA) in the last 730 days?

   ☐ Yes (Go to #3) ☐ No (Deny)

3. Does the client have a claim for a disease-modifying anti-rheumatic drug (DMARD) in the last 180 days?

   Examples of DMARDs include azathioprine (IMURAN), cyclosporine (GENGRAF, NEORAL, SANDIMMUNE), hydroxychloroquine (PLAQUENIL), leflunomide (ARAVA), methotrexate (OTREXUP, TREXALL, XATMEP), and sulfasalazine (AZULFIDINE).

   ☐ Yes (Go to #4) ☐ No (Deny)

4. Does the client have a history of hematologic abnormalities such as aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, or decreased white blood cell counts in the last 60 days?

   ☐ Yes (Deny) ☐ No (Go to #5)

5. Does the client have a serious active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days?

   ☐ Yes (Deny) ☐ No (Got to #6)

6. Does the client have a diagnosis of active hepatic disease or hepatic impairment in the last 365 days?

   ☐ Yes (Deny) ☐ No (Approve – 365 days)

STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: **855-668-8553**

Prescriber Signature: _____ **Date:** _____

If criteria not met, submit chart documentation with form citing complex medical circumstances.

For questions, please call Navitus Customer Care at 1-877-908-6023.